Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Salarius Pharmaceuticals stock

Learn how to easily invest in Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 16 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Salarius Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – SLRX. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Salarius Pharmaceuticals stock price (NASDAQ: SLRX)

Use our graph to track the performance of SLRX stocks over time.

Salarius Pharmaceuticals shares at a glance

Information last updated 2023-01-25.
Latest market close$2.42
52-week range$1.07 - $13.46
50-day moving average $1.91
200-day moving average $4.29
Wall St. target price$70.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.38

Buy Salarius Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Salarius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Salarius Pharmaceuticals price performance over time

Historical closes compared with the close of $2.42 from 2023-01-27

1 week (2023-01-23) -15.09%
1 month (2022-12-30) 58.17%
3 months (2022-10-28) 19.21%
6 months (2022-07-29) 1,173.68%
1 year (2022-01-28) 462.79%
2 years (2021-01-29) 118.02%
3 years (2020-01-30) 2.65
5 years (2018-01-30) 4.19

Salarius Pharmaceuticals financials

Gross profit TTM $-6,708,304
Return on assets TTM -40.33%
Return on equity TTM -99.02%
Profit margin 0%
Book value $7.39
Market capitalisation $5.6 million

TTM: trailing 12 months

Salarius Pharmaceuticals share dividends

We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.

Have Salarius Pharmaceuticals's shares ever split?

Salarius Pharmaceuticals's shares were split on a 1:25 basis on 16 October 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.

Salarius Pharmaceuticals share price volatility

Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $1.07 up to $13.4575. A popular way to gauge a stock's volatility is its "beta".

SLRX.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 0.8391. This would suggest that Salarius Pharmaceuticals's shares are less volatile than average (for this exchange).

Salarius Pharmaceuticals overview

Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Salarius Pharmaceuticals is owned by insiders or institutions?
Currently 8.271% of Salarius Pharmaceuticals shares are held by insiders and 16.327% by institutions.
How many people work for Salarius Pharmaceuticals?
Latest data suggests 16 work at Salarius Pharmaceuticals.
When does the fiscal year end for Salarius Pharmaceuticals?
Salarius Pharmaceuticals's fiscal year ends in December.
Where is Salarius Pharmaceuticals based?
Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021
What is Salarius Pharmaceuticals's ISIN number?
Salarius Pharmaceuticals's international securities identification number is: US79400X1072
What is Salarius Pharmaceuticals's CUSIP number?
Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 79400X107

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site